Angiotensin and systems thinking: Wrapping your mind around the big picture

Ochsner Journal

Volumn 13, Issue 1, 2013, Pages 11-25

  Smith, Gary Robert ^a  

^a Research Department   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERLEUKIN 2; RENIN;

BIOLOGICAL MODEL; BLOOD PRESSURE REGULATION; CELLULAR STRESS RESPONSE; CHRONIC INFLAMMATION; CORNEA ULCER; DISEASE ASSOCIATION; DISEASE COURSE; DRUG POTENTIATION; EDITORIAL; ENZYME INHIBITION; HEART MUSCLE FIBROSIS; HOMEOSTASIS; HUMAN; IMMUNE DEFICIENCY; INFLAMMATION; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MICROANGIOPATHY; MUSCLE INJURY; NONHUMAN; PREDICTION; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYMPTOM; TISSUE INJURY; TISSUE REGENERATION; TISSUE REPAIR; WOUND HEALING;

EID: 84875124445     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (123)

1. Senge PM. The Fifth Discipline: The Art and Practice of the Learning Organization. New York, NY: Doubleday/Currency; 1990.
2. Rook GA. Hygiene hypothesis and autoimmune diseases. Clin Rev Allergy Immunol. 2012 Feb;42(1):5-15.
3. Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y. Vaccines and autoimmunity. Nat Rev Rheumatol. 2009 Nov;5(11):648-652.
4. Greer JB, O'Keefe SJ. Microbial induction of immunity, inflammation, and cancer. Front Physiol. 2011 Jan 26;1:168.
5. Corsini E, Liesivuori J, Vergieva T, Van Loveren H, Colosio C. Effects of pesticide exposure on the human immune system. Hum Exp Toxicol. 2008 Sep;27(9):671-680.
6. Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity-friends or foes? Trends Immunol. 2009 Aug; 30(8):409-414. Epub 2009 Jul 28.
7. Hewison M. Vitamin D and innate and adaptive immunity. Vitam Horm. 2011;86:23-62.
8. Chighizola C, Meroni PL. The role of environmental estrogens and autoimmunity. Autoimmun Rev. 2012 May;11(6-7):A493-A501. Epub 2011 Dec 4.
9. Kuhn TS. The Structure of Scientific Revolutions. Chicago, IL: University of Chicago Press; 1962:52.
10. Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol. 2006 Feb;16(1):38-52 Epub 2005 Aug 31.
11. Sheng KC, Wright MD, Apostolopoulos V. Inflammatory mediators hold the key to dendritic cell suppression and tumor progression. Curr Med Chem. 2011;18(36):5507-5518.
12. Gentile LF, Cuenca AG, Efron PA, et al. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg. 2012 Jun;72(6):1491-1501.
13. Kanterman J, Sade-Feldman M, Baniyash M. New insights into chronic inflammation-induced immunosuppression. Semin Cancer Biol. 2012 Aug;22(4):307-318. Epub 2012 Feb 24.
14. Phillips MI, Schmidt-Ott KM. The discovery of renin 100 years ago. News Physiol Sci. 1999 Dec;14:271-274.
15. Basso N, Terragno NA. History about the discovery of the reninangiotensin system. Hypertension. 2001 Dec 1;38(6):1246-1249.
16. Ritter JM. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension. BMJ. 2011 Apr 7; 342:d1673.
17. George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer. 2010 Nov;10(11):745-759. Epub 2010 Oct 22.
18. Young D, Waitches G, Birchmeier C, Fasano O, Wigler M. Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell. 1986 Jun 6;45(5):711-719.
19. Chappell MC. Emerging evidence for a functional angiotensinconverting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure? Hypertension. 2007 Oct;50(4):596-599. Epub 2007 Sep 4.
20. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002 Nov;62(5):1524-1538.
21. Smith GR, Missailidis S. Learning from cancer: The adaptive growth, wound and immune responses. Gene Ther Mol Biol. 2009 Jun;13:158-185.
22. Zhao X, Wu ZX, Zhang Y, et al. Locally administrated perindopril improves healing in an ovariectomized rat tibial osteotomy model. PLoS One. 2012;7(3):e33228. Epub 2012 Mar 13.
23. Garcia P, Schwenzer S, Slotta JE, et al. Inhibition of angiotensin-converting enzyme stimulates fracture healing and periosteal callus formation-role of a local renin-angiotensin system. Br J Pharmacol. 2010 Apr;159(8):1672-1680. Epub 2010 Mar 5.
24. Rodgers K, Verco S, Bolton L, Dizerega G. Accelerated healing of diabetic wounds by NorLeu(3)-angiotensin (1-7). Expert Opin Investig Drugs. 2011 Nov;20(11):1575-1581. Epub 2011 Oct 6.
25. Biernacka A, Frangogiannis NG. Aging and cardiac fibrosis. Aging Dis. 2011 Apr;2(2):158-173.
26. Wu HJ, Liu HW, Cheng B, et al. [The change of angiotensin II production and its receptor expression during wound healing: possible role of angiotensin II in wound healing]. Zhonghua Zheng Xing Wai Ke Za Zhi. 2011 Mar;27(2):124-128. Chinese.
27. Mizoue S, Iwai M, Ide A, et al. Role of angiotensin II receptor subtypes in conjunctival wound healing. Curr Eye Res. 2006 Feb;31(2):129-136.
28. Kurosaka M, Suzuki T, Hosono K, et al. Reduced angiogenesis and delay in wound healing in angiotensin II type 1a receptordeficient mice. Biomed Pharmacother. 2009 Nov;63(9):627-634 Epub 2009 Feb 14.
29. Steckelings UM, Henz BM, Wiehstutz S, Unger T, Artuc M. Differential expression of angiotensin receptors in human cutaneous wound healing. Br J Dermatol. 2005 Nov;153(5): 887-893.
30. Chesnokova NB, Kost OA, Nikol'skaia II, et al. [Mental rationale for local use of angiotensin-converting enzyme in the treatment of inflammatory processes in the eye]. Vestn Oftalmol. 2008 Mar-Apr;124(2):16-19. Russian.
31. Bedair HS, Karthikeyan T, Quintero A, Li Y, Huard J. Angiotensin II receptor blockade administered after injury improves muscle regeneration and decreases fibrosis in normal skeletal muscle. Am J Sports Med. 2008 Aug;36(8):1548-1554. Epub 2008 Jun 11; Erratum in: Am J Sports Med. 2008 Dec;36(12):2465.
32. Garrido-Gil P, Valenzuela R, Villar-Cheda B, Lanciego JL, Labandeira-Garcia JL. Expression of angiotensinogen and receptors for angiotensin and prorenin in the monkey and human substantia nigra: an intracellular renin-angiotensin system in the nigra. Brain Struct Funct. 2012 Mar 11. [Epub ahead of print].
33. Thethi T, Kamiyama M, Kobori H. The link between the reninangiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome. Curr Hypertens Rep. 2012 Apr;14(2): 160-169.
34. Neo JH, Ager EI, Angus PW, et al. Changes in the renin angiotensin system during the development of colorectal cancer liver metastases. BMC Cancer. 2010 Apr 10;10:134.
35. Kaschina E, Scholz H, Steckelings UM, et al. Transition from atherosclerosis to aortic aneurysm in humans coincides with an increased expression of RAS components. Atherosclerosis. 2009 Aug;205(2):396-403. Epub 2009 Jan 13.
36. Beyazit Y, Aksu S, Haznedaroglu IC, et al. Overexpression of the local bone marrow renin-angiotensin system in acute myeloid leukemia. J Natl Med Assoc. 2007 Jan;99(1):57-63.
37. Chalmers L, Kaskel FJ, Bamgbola O. The role of obesity and its bioclinical correlates in the progression of chronic kidney disease. Adv Chronic Kidney Dis. 2006 Oct;13(4):352-364.
38. Graciano ML, Cavaglieri Rde C, Dellê H, et al. Intrarenal Renin-Angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis. J Am Soc Nephrol. 2004 Jul;15(7):1805-1815.
39. Tsang SW, Cheng CH, Leung PS. The role of the pancreatic renin-angiotensin system in acinar digestive enzyme secretion and in acute pancreatitis. Regul Pept. 2004 Jul 15;119(3):213-219.
40. Johnston AP, Baker J, De Lisio M, Parise G. Skeletal muscle myoblasts possess a stretch-responsive local angiotensin signalling system. J Renin Angiotensin Aldosterone Syst. 2011 Jun;12(2):75-84. Epub 2010 Oct 4.
41. Jiang JS, Lang YD, Chou HC, et al. Activation of the reninangiotensin system in hyperoxia-induced lung fibrosis in neonatal rats. Neonatology. 2012;101(1):47-54. Epub 2011 Jul 26.
42. Takao T, Horino T, Kagawa T, et al. Possible involvement of intracellular angiotensin II receptor in high-glucose-induced damage in renal proximal tubular cells. J Nephrol. 2011 Mar-Apr;24(2):218-224.
43. Krick S, Hänze J, Eul B, et al. Hypoxia-driven proliferation of human pulmonary artery fibroblasts: cross-talk between HIF-1alpha and an autocrine angiotensin system. FASEB J. 2005 May;19(7):857-859. Epub 2005 Feb 17.
44. Yasuda N, Akazawa H, Qin Y, Zou Y, Komuro I. A novel mechanism of mechanical stress-induced angiotensin II type 1-receptor activation without the involvement of angiotensin II. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6): 393-399. Epub 2007 Nov 29.
45. Hitomi H, Fukui T, Moriwaki K, et al. Synergistic effect of mechanical stretch and angiotensin II on superoxide production via NADPH oxidase in vascular smooth muscle cells. J Hypertens. 2006 Jun;24(6):1089-1095.
46. Delli Gatti C, Osto E, Kouroedov A, et al. Pulsatile stretch induces release of angiotensin II and oxidative stress in human endothelial cells: effects of ACE inhibition and AT1 receptor antagonism. Clin Exp Hypertens. 2008 Oct;30(7):616-627.
47. Watanabe T, Pakala R, Katagiri T, Benedict CR. Mildly oxidized low-density lipoprotein acts synergistically with angiotensin II in inducing vascular smooth muscle cell proliferation. J Hypertens. 2001 Jun;19(6):1065-1073.
48. Li DY, Zhang YC, Philips MI, Sawamura T, Mehta JL. Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res. 1999 May 14;84(9):1043-1049.
49. Nickenig G, Sachinidis A, Seewald S, Böhm M, Vetter H. Influence of oxidized low-density lipoprotein on vascular angiotensin II receptor expression. J Hypertens Suppl. 1997 Dec;15(6):S27-S30.
50. Hu C, Dandapat A, Sun L, et al. Modulation of angiotensin IImediated hypertension and cardiac remodeling by lectin-like oxidized low-density lipoprotein receptor-1 deletion. Hypertension. 2008 Sep;52(3):556-562. Epub 2008 Jul 21.
51. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57-70.
52. Anand P, Kunnumakkara AB, Sundaram C, et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res. 2008 Sep;25(9):2097-2116. Epub 2008 Jul 15. Erratum in: Pharm Res. 2008 Sep;25(9):2200.
53. Azad N, Rojanasakul Y, Vallyathan V. Inflammation and lung cancer: roles of reactive oxygen/nitrogen species. J Toxicol Environ Health B Crit Rev. 2008 Jan;11(1):1-15.
54. Munteanu I, Didilescu C. [Chemistry and toxicology of cigarette smoke in the lungs]. Pneumologia. 2007 Jan-Mar;56(1):41, 43-
55. Brody JS, Spira A. State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer. Proc Am Thorac Soc. 2006 Aug;3(6):535-537.
56. Smith CJ, Perfetti TA, King JA. Perspectives on pulmonary inflammation and lung cancer risk in cigarette smokers. Inhal Toxicol. 2006 Aug;18(9):667-677.
57. Smith GR, Missailidis S. Cancer, inflammation and the AT1 and AT2 receptors. J Inflamm (Lond). 2004 Sep 30;1(1):3.
58. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008 Oct 6;27(45):5904-5912.
59. Menke MN, Menke NB, Boardman CH, Diegelmann RF. Biologic therapeutics and molecular profiling to optimize wound healing. GynecolOncol. 2008 Nov;111(2 Suppl):S87-S91. Epub 2008 Oct 1.
60. Dalgleish AG, O'Byrne K. Inflammation and cancer: the role of the immune response and angiogenesis. Cancer Treat Res. 2006;130:1-38.
61. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646-674.
62. Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett. 2008 Aug 28;267(2): 204-215. Epub 2008 Apr 29.
63. Whiteside TL. The role of immune cells in the tumor microenvironment. Cancer Treat Res. 2006;130:103-124.
64. Lee JM, Yanagawa J, Peebles KA, et al. Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol. 2008 Jun;66(3):208-217, Epub 2008 Mar 4.
65. Peebles KA, Lee JM, Mao JT, et al. Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Rev Anticancer Ther. 2007 Oct;7(10):1405-1421.
66. Erlinger TP, Muntner P, Helzlsouer KJ. WBC count and the risk of cancer mortality in a national sample of U.S. adults: results from the Second National Health and Nutrition Examination Survey mortality study. Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):1052-1056.
67. Shankar A, Wang JJ, Rochtchina E, Yu MC, Kefford R, Mitchell P. Association between circulating white blood cell count and cancer mortality: a population-based cohort study. Arch Intern Med. 2006 Jan 23;166(2):188-194. Erratum in: Arch Intern Med. 2006 Mar 27;166(6):681.
68. Taranova AG, Maldonado D 3rd, Vachon CM, et al. Allergic pulmonary inflammation promotes the recruitment of circulating tumor cells tothe lung. CancerRes.2008Oct15;68(20):8582-8589.
69. Ingber DE. Can cancer be reversed by engineering the tumor microenvironment? Semin Cancer Biol. 2008 Oct;18(5):356-364, Epub 2008 Apr 1.
70. Fujita M, Hayashi I, Yamashina S, et al. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis. 2005 Feb; 26(2):271-279. Epub 2005 Jan 6.
71. Imai N, Hashimoto T, Kihara M, et al. Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumorassociated angiogenesis. Lab Invest. 2007 Feb;87(2):189-198. Epub 2006 Dec 18.
72. Hoshino K, Ishiguro H, Teranishi J, et al. Regulation of androgen receptor expression through angiotensin II type 1 receptor in prostate cancer cells. Prostate. 2011 Jun 15;71(9):964-975. Epub 2010 Dec 28.
73. Doi C, Egashira N, Kawabata A, et al. Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice. BMC Cancer. 2010 Feb 24;10:67.
74. Clere N, Corre I, Faure S, et al. Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. Int J Cancer. 2010 Nov 15;127(10):2279-2291.
75. Shen XZ, Li P, Weiss D, Fuchs S, et al. Mice with enhanced macrophage angiotensin-converting enzyme are resistant to melanoma. Am J Pathol. 2007 Jun;170(6):2122-2134.
76. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010 Jul;11(7): 627-636. Epub 2010 Jun 11.
77. Sica DA. Angiotensin receptor blockers and the risk of malignancy: a note of caution. Drug Saf. 2010 Sep 1;33(9):709-712.
78. Aalbers J. ARBs and possible cancer risk. Cardiovasc J Afr. 2010 Jul-Aug;21(4):232.
79. Bloch MJ, Basile JN. Meta-analysis concludes angiotensin receptor blocker use increases the risk of developing cancer: concerns about the science and the message. J Clin Hypertens (Greenwich). 2010 Sep;12(9):661-663. Epub 2010 Aug 24.
80. Volpe M, Azizi M, Danser AH, Nguyen G, Ruilope LM. Twisting arms to angiotensin receptor blockers/antagonists: the turn of cancer. Eur Heart J. 2011 Jan;32(1):19-22. Epub 2010 Oct 21.
81. Madsen FF. [Angiotensin II type 1 receptor blockade and risk of cancer]. Ugeskr Laeger. 2010 Nov 1;172(44):3054; discussion 3054. Danish.
82. Lombard C, Nosworthy A, Albers J. Opinions in hypertension. ARBs and risk of cancer: international and South African expert comment. Cardiovasc J Afr. 2010 Nov-Dec;21(6):338-341.
83. Marina I, Krakoff LR. Angiotensin receptor blockers, cancer, and smoking. J Clin Hypertens (Greenwich). 2010 Dec;12(12):945-948.
84. Cohen DL, Townsend RR. Is there an increased cancer risk associated with the use of angiotensin receptor blockers and should it affect current prescribing? J Clin Hypertens (Greenwich). 2011 Feb;13(2):131-132. Epub 2010 Dec 17.
85. Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011 Jan;12(1):65-82. Epub 2010 Nov 29.
86. ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens. 2011 Apr;29(4): 623-635.
87. Pasternak B, Svanström H, Callréus T, Melbye M, Hviid A. Use of angiotensin receptor blockers and the risk of cancer. Circulation. 2011 Apr 26;123(16):1729-1736. Epub 2011 Apr 11.
88. Yoon C, Yang HS, Jeon I, Chang Y, Park SM. Use of angiotensinconverting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies. CMAJ. 2011 Oct 4;183(14):E1073-E1084. Epub 2011 Aug 29.
89. Cassat M, Wuerzner G, Burnier M, Waeber B. [Angiotensin II receptor blockers (ARBs) and cancer: a reassuring balance]. Rev Med Suisse. 2011 Sep 14;7(308):1757-1758, 1760. French.
90. No connection between ARBs and cancer. Harv Heart Lett. 2011 Aug;21(12):6.
91. Olin JL, Veverka A, Nuzum DS. Risk of cancer associated with the use of angiotensin II-receptor blockers. Am J Health Syst Pharm. 2011 Nov 15;68(22):2139-2146.
92. Wuerzner G, Burnier M, Waeber B. Critical review of cancer risk associated with angiotensin receptor blocker therapy. Vasc Health Risk Manag. 2011;7:741-747. Epub 2011 Dec 12.
93. Singh A, Bangalore S. Which, if any, antihypertensive agents cause cancer? Curr Opin Cardiol. 2012 Jul;27(4):374-380.
94. Huang CC, Chan WL, Chen YC, et al. Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am J Cardiol. 2011 Apr 1;107(7):1028-1033. Epub 2011 Jan 20.
95. Wang KL, Liu CJ, Chao TF, et al. Long-term use of angiotensin II receptor blockers and risk of cancer: A population-based cohort analysis. Int J Cardiol. 2012 Jun 16. [Epub ahead of print].
96. Zeng W, Chen W, Leng X, He JG, Ma H. Chronic angiotensin-(1-7) administration improves vascular remodeling after angioplasty through the regulation of the TGF-beta/Smad signaling pathway in rabbits. Biochem Biophys Res Commun. 2009 Nov 6;389(1):138-144. Epub 2009 Aug 26.
97. Zeng WT, Chen WY, Leng XY, He JG, Ma H. [Angiotensin-(1-7) reduced postangioplasty vascular fibrosis in abdominal aorta of rabbits]. Zhonghua Xin Xue Guan Bing Za Zhi. 2010 Jun;38(6): 531-538. Chinese.
98. Krishnan B, Smith TL, Dubey P, et al. Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis. Prostate. 2012 May 29. [Epub ahead of print].
99. Kim ST, Park KH, Oh SC, et al. How does inhibition of the reninangiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy? Oncology. 2012;83(6):354-360. Epub 2012 Oct 8.
100. Nakai Y, Isayama H, Sasaki T, et al. Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients. Pancreas. 2012 Sep 20. [Epub ahead of print].
101. Nakai Y, Isayama H, Ijichi H, et al. Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1. Cancer Sci. 2012 Aug;103(8):1489-1492. Epub 2012 Jun 15.
102. Tanaka N, Miyajima A, Kikuchi E, et al. Prognonstic impact of renin-angiotensin system blockade in localised upper-tract urothelial carcinoma. Br J Cancer. 2012 Jan 17;106(2):290-296, Epub 2011 Dec 20.
103. Mc Menamin ÚC, Murray LJ, Cantwell MM, Hughes CM. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review. Cancer Causes Control. 2012 Feb;23(2): 221-230. Epub 2011 Nov 25.
104. Keizman D, Huang P, Eisenberger MA, et al. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer. 2011 Sep;47(13):1955-1961. Epub 2011 May 18.
105. Tatokoro M, Fujii Y, Kawakami S, et al. Phase-II trial of combination treatment of interferon-a, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma. Cancer Sci. 2011 Jan;102(1):137-143. Epub 2010 Oct 26.
106. Kaibori M, Ishizaki M, Matsui K, Kitade H, Matsui Y, Kwon AH. Evaluation of metabolic factors on the prognosis of patients undergoing resection of hepatocellular carcinoma. J Gastroenterol Hepatol. 2011 Mar;26(3):536-543.
107. Nakai Y, Isayama H, Ijichi H, et al. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer. 2010 Nov 23;103(11): 1644-1648. Epub 2010 Oct 26.
108. Wilop S, von Hobe S, Crysandt M, et al. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol. 2009 Oct;135(10):1429-1435. Epub 2009 Apr 28.
109. Uemura H, Hasumi H, Kawahara T, et al. Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol. 2005 Dec;10(6):405-410.
110. Chae YK, Valsecchi ME, Kim J, et al. Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest. 2011 Nov;29(9):585-593. Epub 2011 Sep 21.
111. Yuge K, Miyajima A, Tanaka N, et al. Prognostic value of reninangiotensin system blockade in non-muscle-invasive bladder cancer. Ann Surg Oncol. 2012 Nov;19(12):3987-3993. Epub 2012 Aug 8.
112. Yoshiji H, Noguchi R, Ikenaka Y, et al. Combination of branchedchain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial. Oncol Rep. 2011 Dec; 26(6):1547-1553. Epub 2011 Aug 24.
113. Ronquist G, Frithz G, Wang YH, Lindeborg T. Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer. Scand J Urol Nephrol. 2009;43(1):32-36.
114. Wedlake LJ, Silia F, Benton B, et al. Evaluating the efficacy of statins and ACE-inhibitors in reducing gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignancies. Eur J Cancer. 2012 Sep;48(14):2117-2124. Epub 2012 Mar 3.
115. Kharofa J, Cohen EP, Tomic R, Xiang Q, Gore E. Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy. Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):238-243, Epub 2012 Jan 31.
116. Dessì M, Piras A, Madeddu C, et al. Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicininduced inflammation, oxidative stress and myocardial dysfunction. Exp Ther Med. 2011 Sep;2(5):1003-1009. Epub 2011 Jun 30.
117. Abedon ST. Bacterial 'immunity' against bacteriophages. Bacteriophage. 2012 Jan 1;2(1):50-54.
118. Dai Z, Wu F, Yeung EW, Li Y. IGF-IEc expression, regulation and biological function in different tissues. Growth Horm IGF Res. 2010 Aug;20(4):275-281. Epub 2010 May 21.
119. Teboul M, Guillaumond F, Gréchez-Cassiau A, Delaunay F. The nuclear hormone receptor family round the clock. Mol Endocrinol. 2008 Dec;22(12):2573-2582. Epub 2008 Jul 24.
120. Duong V, Rochette-Egly C. The molecular physiology of nuclear retinoic acid receptors. From health to disease. Biochim Biophys Acta. 2011 Aug;1812(8):1023-1031. Epub 2010 Oct 20.
121. Pan D, Kocherginsky M, Conzen SD. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res. 2011 Oct 15;71(20):6360-6370. Epub 2011 Aug 25.
122. Reis e Sousa C. Activation of dendritic cells: translating innate into adaptive immunity. Curr Opin Immunol. 2004 Feb;16(1):21-25.
123. Hoyer KK, Dooms H, Barron L, Abbas AK. Interleukin-2 in the development and control of inflammatory disease. Immunol Rev. 2008 Dec;226:19-28.